Summary
- Current Price
- As of today, VRTX price is $423.24, down -1.60% on
- Current Price All-Time High
- VRTX price is currently -18.59% below its historical high of $519.88 set on
- Market Cap
- VRTX current market cap is $108B, down -16.79% year-over-year
- PE Ratio
- VRTX current PE ratio is 27.60
- Revenue
- VRTX current annual revenue is $12.07B, up +9.92% year-over-year
- Next Earnings
- The next earnings release for VRTX is on
Profile
| Metric | Value |
|---|---|
| Full Name | Vertex Pharmaceuticals Incorporated |
| Ticker | NASDAQ: VRTX |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | |
| Website | vrtx.com |
| Employees | 6,100 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $423.24 | |
| Price, 1D Change | -1.60% | |
| Market Cap | $108B | |
| - | ||
| PE Ratio | 27.60 | |
| Beta | 0.82 | |
| Revenue | $12B | |
| Revenue, 1Y Change | +9.92% | |
| EPS | $15.32 | |
| EPS, 1Y Change | +837.79% |
Chart
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 2:1 | |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $15.32 | |
| EPS Estimate | N/A | $19.04 |
| EPS Est. Change | N/A | +24.26% |
| Revenue | $12.07B | |
| Revenue Estimate | N/A | $13.02B |
| Revenue Est. Change | N/A | +7.83% |
| Current Price | $423.24 | |
| Price Target | - | $559.50 |
| Price Tgt. Change | - | +32.19% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $0.48 | -$2.08 | -528.47% | |
| $18.43 | $15.32 | -16.88% | |
| $19.04 | N/A | +24.26% | |
| $21.78 | N/A | +42.12% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $10.88B | $10.98B | +0.96% | |
| $11.98B | $12.07B | +0.77% | |
| $13.02B | N/A | +7.83% | |
| $14.33B | N/A | +18.67% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | -15.94% | |
| Price, 3Y | +24.22% | |
| Market Cap, 1Y | -16.79% | |
| Market Cap, 3Y | +22.68% | |
| Revenue, 1Y | +9.92% | |
| Revenue, 3Y | +38.02% | |
| EPS, 1Y | +837.79% | |
| EPS, 3Y | +19.51% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $423.24 | |
| SMA 200 | $436.61 | |
| SMA 200 vs Price | +3.16% | |
| SMA 50 | $455.29 | |
| SMA 50 vs Price | +7.57% | |
| Beta | 0.82 | |
| ATR | $10.04 | |
| 14-Day RSI | 37.11 | |
| 10-Day Volatility | 15.33% | |
| 1-Year Volatility | 35.66% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $12.07B | |
| EPS | $15.32 | |
| Gross Profit | $10.27B | |
| Gross Margin | 85.03% | |
| Operating Profit | $4.69B | |
| Operating Margin | 39.06% | |
| Net Income | $3.95B | |
| Net Margin | 32.94% | |
| EBITDA | $4.97B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.10 | |
| Current Ratio | 2.90 | |
| Quick Ratio | 2.46 | |
| - | ||
| F-Score | 6 | |
| Altman Z-Score | 10.76 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 27.60 | |
| PS Ratio | 8.92 | |
| PB Ratio | 5.77 | |
| EV/EBITDA | 20.83 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $18.67B | |
| Cash & Equivalents | $6.61B | |
| Total Assets | $26.14B | |
| Current Assets | $11.20B | |
| Total Liabilities | $7.48B | |
| Current Liabilities | $3.86B | |
| Total Debt | $2.04B | |
| Short Term Debt | $82.80M | |
| Accounts Payable | $461.70M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $8.05B | |
| Operating Expenses | $5.68B | |
| Cost Of Goods Sold | $1.81B | |
| SG&A | $0.00 | |
| D&A | $209.80M | |
| Interest Expense | $0.00 | |
| Income Tax | $690.00M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $3.63B | |
| CFI | -$945.40M | |
| CFF | -$2.26B | |
| Capex | $437.60M | |
| Free Cash Flow | $3.19B |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Morgan Stanley | → | |
| Maxim Group | → | |
| Truist Securities | → | |
| Oppenheimer | → | |
| Morgan Stanley | → | |
| Jefferies | ||
| HC Wainwright & Co. | → | |
| Citigroup | → | |
| B of A Securities | → | |
| HC Wainwright & Co. | → |
Analyst sentiment
Institutional ownership
Screeners with VRTX
FAQ
What is the ticker symbol for Vertex Pharmaceuticals Incorporated?
The ticker symbol for Vertex Pharmaceuticals Incorporated is NASDAQ:VRTX
Does Vertex Pharmaceuticals Incorporated pay dividends?
No, Vertex Pharmaceuticals Incorporated does not pay dividends
What sector is Vertex Pharmaceuticals Incorporated in?
Vertex Pharmaceuticals Incorporated is in the Healthcare sector
What industry is Vertex Pharmaceuticals Incorporated in?
Vertex Pharmaceuticals Incorporated is in the Biotechnology industry
What country is Vertex Pharmaceuticals Incorporated based in?
Vertex Pharmaceuticals Incorporated is headquartered in United States
When did Vertex Pharmaceuticals Incorporated go public?
Vertex Pharmaceuticals Incorporated initial public offering (IPO) was on July 24, 1991
Is Vertex Pharmaceuticals Incorporated in the S&P 500?
Yes, Vertex Pharmaceuticals Incorporated is included in the S&P 500 index
Is Vertex Pharmaceuticals Incorporated in the NASDAQ 100?
Yes, Vertex Pharmaceuticals Incorporated is included in the NASDAQ 100 index
Is Vertex Pharmaceuticals Incorporated in the Dow Jones?
No, Vertex Pharmaceuticals Incorporated is not included in the Dow Jones index
When was Vertex Pharmaceuticals Incorporated last earnings report?
Vertex Pharmaceuticals Incorporated's most recent earnings report was on February 12, 2026
When does Vertex Pharmaceuticals Incorporated report earnings?
The next expected earnings date for Vertex Pharmaceuticals Incorporated is May 4, 2026
Data Sources & References
- VRTX Official Website www.vrtx.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.htm
- List of S&P 500 Companies www.spglobal.com/spdji/en/indices/equity/sp-500/#overview
- List of NASDAQ 100 Companies www.nasdaq.com/market-activity/quotes/nasdaq-ndx-index
- VRTX Profile on Yahoo Finance finance.yahoo.com/quote/VRTX
- VRTX Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/vrtx